Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 30;10(1):25-36.
doi: 10.3390/tomography10010003.

Residual Lung Abnormalities in Survivors of Severe or Critical COVID-19 at One-Year Follow-Up Computed Tomography: A Narrative Review Comparing the European and East Asian Experiences

Andrea Borghesi  1 , Pietro Ciolli  1 , Elisabetta Antonelli  1 , Alessandro Monti  1 , Alessandra Scrimieri  1 , Marco Ravanelli  1 , Roberto Maroldi  1 , Davide Farina  1
Affiliations
Review

Residual Lung Abnormalities in Survivors of Severe or Critical COVID-19 at One-Year Follow-Up Computed Tomography: A Narrative Review Comparing the European and East Asian Experiences

Andrea Borghesi et al. Tomography. .

Abstract

The literature reports that there was a significant difference in the medical impact of the coronavirus disease (COVID-19) pandemic between European and East Asian countries; specifically, the mortality rate of COVID-19 in Europe was significantly higher than that in East Asia. Considering such a difference, our narrative review aimed to compare the prevalence and characteristics of residual lung abnormalities at one-year follow-up computed tomography (CT) after severe or critical COVID-19 in survivors of European and East Asian countries. A literature search was performed to identify articles focusing on the prevalence and characteristics of CT lung abnormalities in survivors of severe or critical COVID-19. Database analysis identified 16 research articles, 9 from Europe and 7 from East Asia (all from China). Our analysis found a higher prevalence of CT lung abnormalities in European than in Chinese studies (82% vs. 52%). While the most prevalent lung abnormalities in Chinese studies were ground-glass opacities (35%), the most prevalent lung abnormalities in European studies were linear (59%) and reticular opacities (55%), followed by bronchiectasis (46%). Although our findings required confirmation, the higher prevalence and severity of lung abnormalities in European than in Chinese survivors of COVID-19 may reflect a greater architectural distortion due to a more severe lung damage.

Keywords: COVID-19; SARS-CoV-2; follow-up studies; multidetector computed tomography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Cropped axial thin-section computed tomography (CT) images with lung window setting show some examples of long-term chest CT findings in survivors of coronavirus disease (COVID-19): (a) ground-glass and subpleural curvilinear opacities; (b) reticular opacities with architectural distortion and bronchiectasis; (c) reticular opacities with architectural distortion and traction bronchiectasis.
Figure 2
Figure 2
Prevalence of different types of CT lung abnormalities in survivors of severe or critical COVID-19 at one-year follow-up (European studies). ANY, any residual lung abnormalities; GGO, ground-glass opacities; RO, reticular opacities; LO, linear opacities; C, consolidation; B, bronchiectasis; H, honeycombing.
Figure 3
Figure 3
Prevalence of different types of CT lung abnormalities in survivors of severe or critical COVID-19 at one-year follow-up (Chinese studies). ANY, any residual lung abnormalities; GGO, ground-glass opacities; RO, reticular opacities; LO, linear opacities; C, consolidation; B, bronchiectasis; H, honeycombing.
See this image and copyright information in PMC

References

    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Cerqua A., Di Stefano R. When Did Coronavirus Arrive in Europe? Stat. Methods Appl. 2022;31:181–195. doi: 10.1007/s10260-021-00568-4. - DOI - PMC - PubMed
    1. Borghesi A., Maroldi R. COVID-19 Outbreak in Italy: Experimental Chest X-Ray Scoring System for Quantifying and Monitoring Disease Progression. Radiol. Med. 2020;125:509–513. doi: 10.1007/s11547-020-01200-3. - DOI - PMC - PubMed
    1. World Health Organization (WHO) Europe—Coronavirus Disease (COVID-19) Pandemic. [(accessed on 7 October 2023)]. Available online: https://www.who.int/europe/emergencies/situations/covid-19.
    1. Lopez Bernal J., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., Simmons R., Cottrell S., Roberts R., O’Doherty M., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study. BMJ. 2021;373:n1088. doi: 10.1136/bmj.n1088. - DOI - PMC - PubMed